image
Healthcare - Biotechnology - NASDAQ - US
$ 1.51
-9.03 %
$ 151 M
Market Cap
-1.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ALEC stock under the worst case scenario is HIDDEN Compared to the current market price of 1.51 USD, Alector, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ALEC stock under the base case scenario is HIDDEN Compared to the current market price of 1.51 USD, Alector, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ALEC stock under the best case scenario is HIDDEN Compared to the current market price of 1.51 USD, Alector, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALEC

image
$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.815 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
101 M REVENUE
3.60%
-145 M OPERATING INCOME
4.44%
-119 M NET INCOME
8.70%
-230 M OPERATING CASH FLOW
-24.84%
107 M INVESTING CASH FLOW
5.11%
81.5 M FINANCING CASH FLOW
3097.65%
3.67 M REVENUE
-93.23%
-44.7 M OPERATING INCOME
-516.57%
-40.5 M NET INCOME
-1851.35%
-60.8 M OPERATING CASH FLOW
-10.46%
65.7 M INVESTING CASH FLOW
58.77%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Alector, Inc.
image
Current Assets 425 M
Cash & Short-Term Investments 413 M
Receivables 0
Other Current Assets 11.4 M
Non-Current Assets 43.5 M
Long-Term Investments 0
PP&E 37.1 M
Other Non-Current Assets 6.39 M
88.28 %7.92 %Total Assets$468.3m
Current Liabilities 125 M
Accounts Payable 2.22 M
Short-Term Debt 8.75 M
Other Current Liabilities 114 M
Non-Current Liabilities 216 M
Long-Term Debt 33.8 M
Other Non-Current Liabilities 183 M
33.41 %9.89 %53.49 %Total Liabilities$341.5m
EFFICIENCY
Earnings Waterfall Alector, Inc.
image
Revenue 101 M
Cost Of Revenue 0
Gross Profit 91.7 M
Operating Expenses 246 M
Operating Income -145 M
Other Expenses -25.9 M
Net Income -119 M
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)101m092m(246m)(145m)26m(119m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
91.21% GROSS MARGIN
91.21%
-144.19% OPERATING MARGIN
-144.19%
-118.39% NET MARGIN
-118.39%
-93.89% ROE
-93.89%
-25.42% ROA
-25.42%
-41.24% ROIC
-41.24%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alector, Inc.
image
300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -119 M
Depreciation & Amortization -8.97 M
Capital Expenditures -1.26 M
Stock-Based Compensation 39.5 M
Change in Working Capital -147 M
Others -158 M
Free Cash Flow -231 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alector, Inc.
image
Wall Street analysts predict an average 1-year price target for ALEC of $4 , with forecasts ranging from a low of $4 to a high of $4 .
ALEC Lowest Price Target Wall Street Target
4 USD 164.90%
ALEC Average Price Target Wall Street Target
4 USD 164.90%
ALEC Highest Price Target Wall Street Target
4 USD 164.90%
Price
Max Price Target
Min Price Target
Average Price Target
7766554433221100Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Alector, Inc.
image
Sold
0-3 MONTHS
124 K USD 3
3-6 MONTHS
152 K USD 4
6-9 MONTHS
277 K USD 4
9-12 MONTHS
581 K USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET. globenewswire.com - 2 weeks ago
Alector Reports First Quarter 2025 Financial Results and Provides Business Update Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported first quarter 2025 financial results and recent portfolio and business updates. globenewswire.com - 1 month ago
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. globenewswire.com - 1 month ago
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). globenewswire.com - 2 months ago
Alector Provides Executive Leadership Update --Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- globenewswire.com - 2 months ago
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago. zacks.com - 3 months ago
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. globenewswire.com - 3 months ago
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: globenewswire.com - 3 months ago
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. globenewswire.com - 3 months ago
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration globenewswire.com - 5 months ago
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts Bank of America Securities has downgraded Alector, Inc.  ALEC, citing the failure of its AL002 program. benzinga.com - 6 months ago
8. Profile Summary

Alector, Inc. ALEC

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 151 M
Dividend Yield 0.00%
Description Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Contact 131 Oyster Point Boulevard, South San Francisco, CA, 94080 https://www.alector.com
IPO Date Feb. 7, 2019
Employees 175
Officers Dr. Saraswati Kenkare-Mitra Ph.D. President and Head of Research & Development Ms. Danielle Pasqualone J.D., Ph.D. General Counsel Ms. Kristina Cutter M.P.H. Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer Ms. Katie Hogan Senior Director of Corporate Communication & Investor Relations Mr. Giacomo Salvadore M.D. Chief Medical Officer Ms. Clare Hunt M.B.A. Chief People Officer Ms. Virginia DeJesus-Rueff M.B.A. Chief of Staff & Head of Strategy Dr. Arnon Rosenthal Ph.D. Co-Founder, Chief Executive Officer & Director Dr. Marc Grasso M.D. Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer Mr. Neil Berkley M.B.A., M.S. Chief Business Officer